Takeda outlines mid-stage narcolepsy data that prompted 'rapid' move into Phase 3
Takeda presented fleshed-out Phase 2b data for a narcolepsy drug touted by its CEO and reiterated plans to launch …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
